Skip to main content

Peer Review reports

From: SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

Original Submission
24 Mar 2018 Submitted Original manuscript
29 Apr 2018 Author responded Author comments - Soo Young Kim
Resubmission - Version 2
29 Apr 2018 Submitted Manuscript version 2
26 Jul 2018 Author responded Author comments - Soo Young Kim
29 May 2018 Reviewed Reviewer Report - Tai-Jan Chiu
14 May 2018 Reviewed Reviewer Report - Hsiang-Fong Kao
Resubmission - Version 3
26 Jul 2018 Submitted Manuscript version 3
19 Sep 2018 Author responded Author comments - Soo Young Kim
6 Sep 2018 Reviewed Reviewer Report - Tai-Jan Chiu
31 Jul 2018 Reviewed Reviewer Report - Hsiang-Fong Kao
Resubmission - Version 4
19 Sep 2018 Submitted Manuscript version 4
Publishing
24 Sep 2018 Editorially accepted
4 Oct 2018 Article published 10.1186/s12885-018-4854-z

You can find further information about peer review here.

Back to article page